DR. LOUIS C SANFILIPPO, M. D.
Neurology at Hillhouse Ave, New Haven, CT

2013004, Feb 21, 2013

Aug 14, 2012

13/585426

Louis Sanfilippo - New Haven CT, US

LCS GROUP, LLC - New Haven CT

A61K 31/165, A61K 31/496, A61K 31/53, A61P 25/24

514242, 514626, 51425304

The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.

2010016, Jul 1, 2010

Dec 23, 2009

12/646441

Louis Sanfilippo - New Haven CT, US

LCS GROUP, LLC - New Haven CT

A61K 33/00, A61K 31/165, A61K 31/451, A61K 31/496, A61K 31/343, A61K 31/381, A61K 31/55, A61K 31/5375, A61K 31/335, A61K 31/553, A61K 31/42, A61K 31/506, A61K 31/405, A61K 31/404, A61K 31/415, A61K 31/53, A61K 31/551, A61K 31/495, A61K 31/5513, A61K 31/519, A61K 31/454, A61K 31/445, A61K 31/19, A61K 31/4015, A61K 31/4525, A61K 31/35, A61K 31/195, A61K 31/423, A61K 31/428, A61P 25/24, G06Q 90/00

424722, 514626, 514317, 51425411, 514469, 514438, 51421402, 5142392, 51425405, 514450, 51421113, 514217, 514378, 51425215, 514419, 514415, 51425313, 514407, 51425218, 514620, 514245, 514221, 514331, 51425501, 51425409, 51425307, 514220, 51425941, 514323, 514321, 514329, 514557, 514242, 514424, 514326, 514455, 514561, 514379, 514367, 514215, 705500

The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.

2013002, Jan 31, 2013

Oct 3, 2012

13/644156

LCS Group, LLC - New Haven CT, US
Louis Sanfilippo - New Haven CT, US

LCS Group, LLC - New Haven CT

G09B 19/00, A61P 25/30, A61K 49/00

424 92, 434365, 206232

The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the pro drug to treat certain disorders, and optionally one or more other active agents are provided by the invention.

8318813, Nov 27, 2012

Jan 24, 2008

12/666460

Louis Sanfilippo - New Haven CT, US

LCS Group, LLC - New Haven CT

A61K 31/137, A61K 45/06, A61P 25/26, A61P 25/30, A61K 31/4458, A61K 31/16, A61K 31/35, A61K 31/423, A61P 3/04

514654, 514626, 514630

The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.

2007014, Jun 21, 2007

Dec 20, 2006

11/613612

Seth Feuerstein - New Haven CT, US
Ann Coric - New Haven CT, US
Louis Sanfilippo - New Haven CT, US

CENESTRA LLC - New Haven CT

A61K 9/48, A61K 31/202

424451000, 514560000

The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.